

Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over

Information for the public

Published: 23 April 2025

www.nice.org.uk

Leniolisib (Joenja) is available on the NHS as a possible treatment for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[Immunodeficiency UK](https://immunodeficiencyuk.org) (hello@immunodeficiencyuk.org) can give you advice and support.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6940-1